New insider activity at Ocular Therapeutix ( (OCUL) ) has taken place on February 27, 2025.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Recent transactions in Ocular Therapeutix stock reveal significant sales by key executives. CDO Peter Kaiser sold 3,009 shares, amounting to $20,671. CSO Jeffrey S. Heier parted with 3,061 shares for $21,029. President Pravin Dugel made the largest transaction, selling 21,475 shares for $147,533. Additionally, CSO Sanjay Nayak sold 1,895 shares, totaling $12,961.
Recent Updates on OCUL stock
Ocular Therapeutix has recently announced a new compensation package for Pravin Dugel, M.D., in recognition of his expanded roles as Chairman, President, and CEO. This package includes an increased salary, bonus, and long-term equity awards tied to stock performance, aligning his interests with those of shareholders and incentivizing company growth. This strategic decision highlights the company’s commitment to rewarding leadership and enhancing its competitive position in the biopharmaceutical sector.
More about Ocular Therapeutix
YTD Price Performance: -22.54%
Average Trading Volume: 891,271
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.06B
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue